| Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia N Goardon, E Marchi, A Atzberger, L Quek, A Schuh, S Soneji, P Woll, ... Cancer cell 19 (1), 138-152, 2011 | 740 | 2011 |
| Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial AK Burnett, NH Russell, RK Hills, D Bowen, J Kell, S Knapper, YG Morgan, ... The lancet oncology 16 (13), 1295-1305, 2015 | 509 | 2015 |
| A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy S Knapper, AK Burnett, T Littlewood, WJ Kell, S Agrawal, R Chopra, ... Blood 108 (10), 3262-3270, 2006 | 496 | 2006 |
| FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo T Sato, X Yang, S Knapper, P White, BD Smith, S Galkin, D Small, ... Blood, The Journal of the American Society of Hematology 117 (12), 3286-3293, 2011 | 292 | 2011 |
| Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide CN Harrison, AJ Mead, A Panchal, S Fox, C Yap, E Gbandi, A Houlton, ... Blood, The Journal of the American Society of Hematology 130 (17), 1889-1897, 2017 | 161 | 2017 |
| Guideline for the investigation and management of eosinophilia N Butt, J Lambert, S Ali, P Beer, N Cross, A Duncombe, J Ewing, ... British journal of haematology 176 (4), 2017 | 161 | 2017 |
| Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia C Craddock, L Quek, N Goardon, S Freeman, S Siddique, M Raghavan, ... Leukemia 27 (5), 1028-1036, 2013 | 160 | 2013 |
| A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline M McMullin, C Harrison, S Ali, C Cargo, F Chen, J Ewing, M Garg, ... British journal of haematology 184 (2), 2018 | 152 | 2018 |
| The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type … S Knapper, KI Mills, AF Gilkes, SJ Austin, V Walsh, AK Burnett Blood 108 (10), 3494-3503, 2006 | 152 | 2006 |
| A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML S Knapper, N Russell, A Gilkes, RK Hills, RE Gale, JD Cavenagh, ... Blood, The Journal of the American Society of Hematology 129 (9), 1143-1154, 2017 | 150 | 2017 |
| Guideline for the diagnosis and management of myelofibrosis JT Reilly, MF McMullin, PA Beer, N Butt, E Conneally, A Duncombe, ... British journal of haematology 158 (4), 453-471, 2012 | 147 | 2012 |
| Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival AK Burnett, NH Russell, AE Hunter, D Milligan, S Knapper, K Wheatley, ... Blood, The Journal of the American Society of Hematology 122 (8), 1384-1394, 2013 | 138 | 2013 |
| Molecular MRD status and outcome after transplantation in NPM1-mutated AML R Dillon, R Hills, S Freeman, N Potter, J Jovanovic, A Ivey, AS Kanda, ... Blood, The Journal of the American Society of Hematology 135 (9), 680-688, 2020 | 134 | 2020 |
| Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial AJ Mead, D Milojkovic, S Knapper, M Garg, J Chacko, M Farquharson, ... British journal of haematology 170 (1), 29-39, 2015 | 103 | 2015 |
| A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline MFF McMullin, AJ Mead, S Ali, C Cargo, F Chen, J Ewing, M Garg, ... British journal of haematology 184 (2), 161, 2019 | 93 | 2019 |
| FLT3 inhibition in acute myeloid leukaemia S Knapper British journal of haematology 138 (6), 687-699, 2007 | 92 | 2007 |
| Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus in a hematology unit C Moore, M Galiano, A Lackenby, T Abdelrahman, R Barnes, MR Evans, ... Journal of Infectious Diseases 203 (1), 18-24, 2011 | 84 | 2011 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 81 | 2019 |
| A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia CL Andersen, MF McMullin, E Ejerblad, S Zweegman, C Harrison, ... British journal of haematology 162 (4), 498-508, 2013 | 79 | 2013 |
| Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS … AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ... Blood 138, 244, 2021 | 78 | 2021 |
